KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 60% and Risk of Death by 50% for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery
First and only systemic regimen to demonstrate durable survival benefit in this patient population KEYNOTE-905 marks the fifth study of a KEYTRUDA-based regimen... Read more.
ENHERTU® Reduced the Risk of Disease Recurrence or Death by 53% Versus T-DM1 in Patients with High-Risk HER2 Positive Early Breast Cancer Following Neoadjuvant Therapy in DESTINY-Breast05 Phase 3 Trial
More than 92% of patients treated with Daiichi Sankyo and AstraZeneca’s ENHERTU were free of invasive disease at three years DESTINY-Breast05 presented in ESMO... Read more.
ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery resulted in a pathologic complete response in 67% of patients with high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11 Phase III trial
Highest reported pathologic complete response rate seen in a Phase III registrational trial for HER2-positive early breast cancer with favorable safety profile vs.... Read more.
Snap Inc. Deadline: Rosen Law Firm Urges Snap Inc. (NYSE: SNAP) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
NEW YORK–(BUSINESS WIRE)–Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers... Read more.
Infrrd Announces the Official Launch of Ally: The First Agentic AI Workforce for Mortgage Auditing
SAN JOSE, Calif.–(BUSINESS WIRE)–#agenticAI—Infrrd, a global leader in AI-driven document processing solutions, has announced the official launch... Read more.
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 2025
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – OSAKA, Japan & WALTHAM, Mass.–(BUSINESS... Read more.
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen
At five years, KEYTRUDA plus LENVIMA showed a 16.7% overall survival (OS) rate for these patients with mismatch repair proficient (pMMR) advanced endometrial carcinoma... Read more.
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer
Updated data from the Phase 1/2 RAINFOL™-01 trial showed rinatabart sesutecan (Rina-S®) 100 mg/m2 demonstrated 50% confirmed objective response rate (ORR), including... Read more.
Salubris Biotherapeutics Announces Dose Escalation Data for JK06, a 5T4-Targeted Antibody Drug Conjugate, at the European Society for Medical Oncology 2025 Congress
5 confirmed partial responses (PRs) among 13 evaluable non-small cell lung cancer (NSCLC) patients (ORR 38%); 1 confirmed PR among 7 breast cancer patients Favorable... Read more.
Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025
– CABOMETYX reduced the risk of disease progression or death by 81% versus placebo in patients with advanced lung or thymic neuroendocrine tumors (NET) – –... Read more.